GlobeStar Therapeutics Corporation (GSTC) Research

GlobeStar Therapeutics Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing proprietary drug formulations. These innovative treatments specifically target multiple sclerosis (MS) and various other neurodegenerative disorders. Established in 2016, the company was formerly known as AngioSoma, Inc., rebranding to GlobeStar Therapeutics Corporation in July 2021. Its operations are headquartered in Richland, Washington.

Market snapshot

Symbol
GSTC
Price
$0.00
Day change
0.00%
Market cap
$124.1K
P/E ratio
-0.04x
52-week range
0.0001-0.0001
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Acusphere, Inc. (ACUS)
  • Ampio Pharmaceuticals, Inc. (AMPE)
  • Bioasis Technologies Inc. (BIOAF)
  • Ehouse Global, Inc. (EHOS)
  • GB Sciences, Inc. (GBLX)
  • Hard to Treat Diseases Inc. (HTDS)
  • IR Biosciences Holdings Inc. (IRBS)
  • Panbela Therapeutics, Inc. (PBLA)

Recent insider activity

  • Chicoski Robert — trade (0 shares) on 2022-11-23
  • Chicoski Robert — trade (0 shares) on 2021-02-10
  • KATZAROFF JAMES C — J-Other (7042253 shares) on 2023-04-03
  • KATZAROFF JAMES C — J-Other (70422535 shares) on 2023-04-03
  • KATZAROFF JAMES C — A-Award (35000000 shares) on 2023-02-24

Open GlobeStar Therapeutics Corporation (GSTC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.